Opioids in patients with renal impairment

被引:3
作者
Pfefferkorn, Florian [1 ]
Harings-Kaim, Annette [1 ]
Schonenberger, Melanie [2 ]
Leuppi-Taegtmeyer, Anne [1 ]
机构
[1] Univ Spital Basel, Abt Klin Pharmakol & Toxikol, Basel, Switzerland
[2] Univ Spital Basel, Abt Transplantat Immunol & Nephrol, Basel, Switzerland
关键词
PAIN;
D O I
10.1024/0040-5930/a001144
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renal impairment can reduce the elimination of certain opioids and their metabolites. Accumulation and toxicity may occur. Due to their pharmacokinetic properties, fentanyl, alfentanil and buprenorphine can be used safely in patients with renal impairment. Codeine and pethidine should be avoided entirely. Morphine should also be avoided if the creatinine clearance is below 30 ml / min. Reduced dose hydromorphone is an alternative here. Methadone, oxycodone and tramadol should be used with caution and in reduced doses. In this article we briefly explain the renal elimination processes, certain pharmacokinetic properties of the different opioids and the recommendations for clinical practice.
引用
收藏
页码:10 / 13
页数:4
相关论文
共 9 条
  • [1] Ashley C., 2009, RENAL DRUG HDB
  • [2] Haefeli WE, DOSING INFORM ARZNEI
  • [3] Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions
    Leuppi-Taegtmeyer, Anne
    Duthaler, Urs
    Hammann, Felix
    Schmid, Yasmin
    Dickenmann, Michael
    Amico, Patricia
    Jehle, Andreas W.
    Kalbermatter, Stefan
    Lenherr, Christoph
    Schwabedissen, Henriette E. Meyer Zu
    Haschke, Manuel
    Liechti, Matthias E.
    Krahenbuhl, Stephan
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (04) : 692 - 702
  • [4] Liechti ME, 2014, SCHWEIZ MED FORUM, V14, p460
  • [5] Management of pain in end-stage renal disease patients: Short review
    Raina, Rupesh
    Krishnappa, Vinod
    Gupta, Mona
    [J]. HEMODIALYSIS INTERNATIONAL, 2018, 22 (03) : 290 - 296
  • [6] Ritter JFR, 2019, RANG DALES PHARM, V9th
  • [7] Breakthrough Pain Associated with a Reduction in Serum Buprenorphine Concentration during Dialysis
    Salili, Ali Reza
    Mueller, Daniel
    Skendaj, Roswitha
    Jehle, Andreas W.
    Taegtmeyer, Anne B.
    [J]. CLINICAL THERAPEUTICS, 2016, 38 (01) : 212 - 215
  • [8] Swissmedic, ARZN
  • [9] Tegeder I, 1999, SCHMERZ, V13, P183, DOI 10.1007/s004820050197